• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Oncology

Spiritual health may be high among cancer patients in drug clinical trials

byAshley Jackson
November 7, 2023
in Oncology, Wellness
Reading Time: 2 mins read
Survivors of adult-onset cancers associated with increased incidence of cardiovascular disease
Share on FacebookShare on TwitterShare on LinkedIn

1. In this cross-sectional study, cancer patients enrolled in clinical trials demonstrated high levels of spiritual health, which was positively associated with psychological resilience.

2. Furthermore, several factors impacted spiritual health, including religious belief, nationality, and treatment regimen.

Evidence Rating Level: 2 (Good)

As one of the leading causes of death worldwide, cancer places a significant burden on affected individuals. New cancer treatments must undergo clinical trials to assess their safety and effectiveness, leading to many cancer patients participating in these trials. Those who participate in clinical trials tend to have more advanced cancers and often have high expectations for the treatment of interest. As such, these patients are vulnerable to negative feelings and spiritual distress. Therefore, exploring the spiritual needs of cancer patients, particularly those in drug trials, is necessary. This study aimed to investigate the spiritual wellbeing of cancer patients enrolled in clinical trials and assess the factors that contribute to spiritual wellbeing in this population.

This cross-sectional study included 244 cancer patients enrolled in drug clinical trials at the West China Hospital of Sichuan University between December 2022 and July 2023. Participants were included if they were 16 years or older, had a confirmed cancer diagnosis, and were enrolled in a clinical trial. Participants were excluded if they dropped out of the clinical trial part way through or had a concurrent medical condition. Participants completed the Memorial Symptom Assessment Scale Short Form (MSAS-SF), Connor-Davidson Resilience Scale 10 (CD-RISC 10), and Functional Assessment of Chronic Illness Therapy-Spiritual (FACIT-SP) to assess symptom burden, psychological resilience, and spiritual wellbeing, respectively. As well, demographic characteristics and clinical variables were obtained through questionnaires. The primary outcomes were the scores on the different questionnaires and their associations.

The results demonstrated that cancer patients enrolled in clinical trials had high levels of spiritual wellbeing, even more so than standard cancer patients. There was a positive association between psychological resilience and spiritual health and no association between symptom burden score and psychological resilience or spiritual health. Several factors influenced spiritual health, including religious belief, nationality, and treatment regimen. Notably, those patients receiving single antineoplastic therapy demonstrated lower overall spiritual health. However, the study was limited by the inclusion of mainly advanced-stage cancer patients, which may limit the generalizability of the findings to other cancer patients. Nonetheless, the present study demonstrated that spiritual health is high among cancer patients enrolled in clinical trials.

RELATED REPORTS

An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides

Artificial intelligence capable of identifying uncommon gastrointestinal pathologies despite no targeted disease training

Click to read the study in Supportive Care in Cancer

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cancerClinical trialsreligionspiritual healthspiritualitywellness
Previous Post

Selpercatinib vs Chemotherapy and Pembrolizumab in RET Positive NSCLC

Next Post

#VisualAbstract: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

RelatedReports

A calendar, a specimen jar, and a brush are depicted alongside a microscopic view of cervical cells, indicating cervical cancer screening.
All Specialties

An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides

October 23, 2026
An illustration featuring a stomach, DNA helix, and a close-up of Helicobacter pylori bacteria, highlighting genetic susceptibility to gastric conditions.
Artificial Intelligence

Artificial intelligence capable of identifying uncommon gastrointestinal pathologies despite no targeted disease training

October 16, 2026
A collage illustrating the urinary bladder, immune system elements, cancer cells, and an IV bag, highlighting immunotherapy for urothelial cancer.
Chronic Disease

The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality

September 22, 2026
An illustration featuring blood cells and a vial with pills, representing hemophilia and potential treatments for blood coagulation.
Cardiology

Borderline-low hemoglobin levels linked to increased mortality

September 14, 2026
Next Post
#VisualAbstract: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

#VisualAbstract: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

Appropriate use criteria for angiography may frequently miss obstructive coronary artery disease

Myocardial viability testing does not identify patients who benefit from percutaneous coronary intervention

Adalimumab aids in control of noninfectious uveitis

Avacincaptad pegol reduces the rate of age-related macular degeneration in geographic atrophy

✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Optogenetic therapy may partially restore vision in retinitis pigmentosa
  • An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides
  • Elevated low-density lipoprotein cholesterol is a risk factor for atherosclerotic disease irrespective of familial hypercholesterolemia status
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.